CCM
IART icon

Copernicus Capital Management’s Integra LifeSciences IART Stock Holding History

Copernicus Capital Management’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-63,000
Closed -$4.06M – 20
2018
Q2 		$4.06M Buy
+63,000
New +$3.9M 2.95% 16

Other funds holding IART

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Copernicus Capital Management's IART Position: Q3 2018 in Review

Copernicus Capital Management sold out of Integra LifeSciences (IART) in Q3 2018, closing a stake of 63,000 shares — an estimated $4.06M sold.

Copernicus Capital Management first reported a position in IART in Q2 2018 and held it in 1 quarter. The position peaked at $4.06M in Q2 2018. 249 funds tracked by Wall St. Rank hold IART as of Q3 2018.

  • Copernicus Capital Management reported no remaining Integra LifeSciences position as of Q3 2018 after selling out during the quarter.
  • Copernicus Capital Management sold 63,000 Integra LifeSciences shares in Q3 2018, an estimated $4.06M.
  • Copernicus Capital Management first reported a position in Integra LifeSciences in Q2 2018 and held it in 1 quarter.
  • Copernicus Capital Management's Integra LifeSciences position peaked at $4.06M in Q2 2018.
  • 249 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2018.

Based on Copernicus Capital Management's 13F filing for Q3 2018, filed 7 Nov 2018.